Skip to main content

Table 4 Multivariable Cox regression survival analysis of factors associated with risk of relapse

From: Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse

Variable Hazard ratio (95% CI) p
ANCA status at switch to maintenance therapy
 ANCA-positive 1 0.026
 ANCA-negative 0.63 (0.42–0.95)
ANCA specificity at trial entry
 MPO-ANCA 1 0.005
 PR3-ANCA 1.87 (1.21–2.89)
Initial induction treatment
 Daily oral cyclophosphamide 1 0.045
 Pulsed cyclophosphamide 1.52 (1.01–2.29)
Creatinine at entry (per 50 μmol/L) 0.89 (0.83–0.97) 0.004
Initial maintenance therapy
 AZA 1 0.002
 MMF 2.08 (1.38–3.13)
Age (per decade) 0.88 (0.76–1.01) 0.065
Gender 0.98 (0.65–1.49) 0.93
Time to remission 1.0 (0.87–1.15) 0.97
  1. ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, CI confidence interval, MMF mycophenolate mofetil, MPO myeloperoxidase, PR3 proteinase 3